跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 3,890 条关于
“IDH1-mutant gliomas”
全部
3,890
临床试验
2,823
药物
153
机构
9
资讯
905
11个月前
Nuvation Bio Initiates Phase 3 Trial of Safusidenib for High-Grade IDH1-Mutant Glioma Maintenance Treatment
3年前
Vorasidenib Shows Promise as First Targeted Therapy for IDH-Mutant Low-Grade Gliomas
去年
FDA Approves Vorasidenib as Targeted Therapy for IDH-Mutant Gliomas
2年前
FDA Approves Vorasidenib (Voranigo) for IDH-Mutant Grade 2 Glioma
去年
CDSCO Panel Recommends Approval for Vorasidenib with Phase-III Waiver for IDH-Mutant Gliomas in India
2个月前
Vorasidenib Offers Targeted Treatment for IDH-Mutant Low-Grade Gliomas
10个月前
Real-World Study Reveals Treatment Gap in IDH-Mutant Glioma, Supporting Need for Early Intervention
8个月前
Nuvation Bio's IBTROZI Demonstrates Strong Commercial Performance with 432 New Patients in First Six Months
去年
European Regulators Recommend Approval of Vorasidenib for IDH-Mutant Grade 2 Glioma
9个月前
FDA Grants Fast Track Designation to Zotiraciclib for IDH-Mutant Recurrent High-Grade Glioma
第 1 页,共 91 页
上一页
下一页